Literature DB >> 3882004

Reduction of distress in hyperprolactinemia with bromocriptine.

M T Buckman, R Kellner.   

Abstract

In a double-blind placebo-controlled crossover study of bromocriptine in eight hyperprolactinemic patients, self-rated distress decreased and well-being increased parallel with the fall in prolactin levels; for the majority of measures the differences were significant.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3882004     DOI： 10.1176/ajp.142.2.242

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  4 in total

1.  Psychosomatic aspects of galactorrhea.

Authors:  M Langer; J Fiegl; V Riegel; R Prohaska; E Kubista; M Ringler
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

2.  Sexual function in women with hypothalamo-pituitary disorders.

Authors:  B Hulter; P O Lundberg
Journal:  Arch Sex Behav       Date:  1994-04

3.  Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study.

Authors:  Roberto Brugnoli; Diego Novick; Josep Maria Haro; Andrea Rossi; Marco Bortolomasi; Sonia Frediani; Giuseppe Borgherini
Journal:  BMC Psychiatry       Date:  2012-07-19       Impact factor: 3.630

4.  Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin).

Authors:  Deanna L Kelly; Heidi J Wehring; Amber K Earl; Kelli M Sullivan; Faith B Dickerson; Stephanie Feldman; Robert P McMahon; Robert W Buchanan; Dale Warfel; William R Keller; Bernard A Fischer; Joo-Cheol Shim
Journal:  BMC Psychiatry       Date:  2013-08-22       Impact factor: 3.630
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.